CA3114434A1 - Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases - Google Patents
Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases Download PDFInfo
- Publication number
- CA3114434A1 CA3114434A1 CA3114434A CA3114434A CA3114434A1 CA 3114434 A1 CA3114434 A1 CA 3114434A1 CA 3114434 A CA3114434 A CA 3114434A CA 3114434 A CA3114434 A CA 3114434A CA 3114434 A1 CA3114434 A1 CA 3114434A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- pharmaceutical composition
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741270P | 2018-10-04 | 2018-10-04 | |
| US62/741,270 | 2018-10-04 | ||
| US201962853904P | 2019-05-29 | 2019-05-29 | |
| US62/853,904 | 2019-05-29 | ||
| US201962894559P | 2019-08-30 | 2019-08-30 | |
| US62/894,559 | 2019-08-30 | ||
| PCT/US2019/054559 WO2020072814A1 (en) | 2018-10-04 | 2019-10-03 | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3114434A1 true CA3114434A1 (en) | 2020-04-09 |
Family
ID=68318947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3114434A Pending CA3114434A1 (en) | 2018-10-04 | 2019-10-03 | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases |
Country Status (13)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019530713A (ja) | 2016-10-13 | 2019-10-24 | レトロフィン， インコーポレイテッド | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| WO2022246200A1 (en) * | 2021-05-21 | 2022-11-24 | Travere Therapeutics, Inc. | Methods of treating kidney diseases or disorders |
| WO2022266370A1 (en) * | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| WO2001044239A2 (en) | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| WO2010135350A2 (en) | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist |
| US9719981B2 (en) | 2012-08-17 | 2017-08-01 | Father Flanagan's Boys' Home | RAC1 inhibitors for the treatment of alport glomerular disease |
| US10744178B2 (en) * | 2014-08-21 | 2020-08-18 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention and treatment of disease |
| CN109982718A (zh) * | 2016-09-19 | 2019-07-05 | 阿托恩波罗斯生命科学 | 基于环糊精的聚合物、方法、组合物及其应用 |
| JP2019530713A (ja) * | 2016-10-13 | 2019-10-24 | レトロフィン， インコーポレイテッド | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| BR112021012226A2 (pt) | 2018-12-21 | 2021-09-08 | Travere Therapeutics, Inc. | Composições de esparsentano amorfo |
-
2019
- 2019-10-03 JP JP2021518888A patent/JP7524167B2/ja active Active
- 2019-10-03 WO PCT/US2019/054559 patent/WO2020072814A1/en not_active Ceased
- 2019-10-03 CN CN201980079773.4A patent/CN113286587A/zh active Pending
- 2019-10-03 ES ES19791401T patent/ES3057657T3/es active Active
- 2019-10-03 CA CA3114434A patent/CA3114434A1/en active Pending
- 2019-10-03 MA MA053817A patent/MA53817A/fr unknown
- 2019-10-03 US US16/592,633 patent/US11207299B2/en active Active
- 2019-10-03 EP EP19791401.3A patent/EP3860594B1/en active Active
- 2019-10-03 BR BR112021006132-0A patent/BR112021006132A2/pt unknown
- 2019-10-03 MX MX2021003606A patent/MX2021003606A/es unknown
- 2019-10-03 IL IL327175A patent/IL327175A/en unknown
- 2019-10-03 AU AU2019354784A patent/AU2019354784B2/en active Active
- 2019-10-03 KR KR1020217010358A patent/KR102902972B1/ko active Active
-
2021
- 2021-04-01 IL IL281965A patent/IL281965B2/en unknown
-
2024
- 2024-07-17 JP JP2024114026A patent/JP2024133735A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021003606A (es) | 2021-08-16 |
| ES3057657T3 (en) | 2026-03-03 |
| KR102902972B1 (ko) | 2025-12-22 |
| KR20210081338A (ko) | 2021-07-01 |
| AU2019354784A1 (en) | 2021-04-15 |
| US11207299B2 (en) | 2021-12-28 |
| IL281965B2 (en) | 2026-08-01 |
| AU2019354784B2 (en) | 2025-07-10 |
| EP3860594A1 (en) | 2021-08-11 |
| JP2022514152A (ja) | 2022-02-10 |
| MA53817A (fr) | 2021-08-11 |
| JP2024133735A (ja) | 2024-10-02 |
| IL281965A (en) | 2021-05-31 |
| US20200147050A1 (en) | 2020-05-14 |
| WO2020072814A1 (en) | 2020-04-09 |
| BR112021006132A2 (pt) | 2021-07-20 |
| EP3860594B1 (en) | 2025-10-01 |
| JP7524167B2 (ja) | 2024-07-29 |
| IL281965B1 (en) | 2026-04-01 |
| CN113286587A (zh) | 2021-08-20 |
| IL327175A (en) | 2026-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250325522A1 (en) | Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders | |
| US11207299B2 (en) | Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases | |
| WO2022246200A1 (en) | Methods of treating kidney diseases or disorders | |
| KR20260021653A (ko) | IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄 | |
| WO2024073672A1 (en) | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders | |
| HK40059411A (en) | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases | |
| HK40059411B (en) | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases | |
| AU2024343419A1 (en) | Sparsentan for treating immunoglobulin a nephropathy (igan) | |
| CA3071096A1 (en) | Co-administration of minocycline and colistin to reduce acute kidney injury | |
| BR122025008185A2 (pt) | Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241002 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250204 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250210 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250506 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250926 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250926 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251016 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20260216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260805 |